Leqvio vs Losartan: Real-World Evidence Comparison

What These Two Drugs Actually Do

Inclisiran and losartan operate on completely separate physiological targets. Inclisiran is a small interfering RNA that silences hepatic PCSK9 messenger RNA, which causes LDL receptors to stay on the surface of liver cells longer and clear more LDL from the bloodstream. Losartan competitively blocks the angiotensin II type-1 (AT1) receptor, reducing vasoconstriction, aldosterone secretion, and the renin-angiotensin-aldosterone system (RAAS) activity that drives high blood pressure and kidney scarring.

Why They Are Not Substitutes

Choosing between them is not a clinical question that arises in most patients. A cardiologist prescribes inclisiran because a patient's LDL-C remains above goal despite maximally tolerated statin therapy. A physician prescribes losartan because blood pressure is uncontrolled, or the patient has diabetic nephropathy, or heart failure with reduced ejection fraction needs RAAS suppression. The conditions prompting each prescription overlap only partially in the high-risk cardiovascular patient who may need both.

The Exception: Patients Who Ask About Switching

The "switching Leqvio to losartan" question reaches clinicians most often when a patient misunderstands their drug regimen or when a payer's formulary substitution generates confusion. In that context the answer is direct: the two drugs do not replace each other because they treat different biochemical abnormalities. A patient whose LDL-C is still elevated does not benefit from stopping inclisiran and starting losartan instead.

Inclisiran (Leqvio): Clinical Trial Evidence

ORION-10 and ORION-11

The key evidence for inclisiran comes from two phase 3 randomized controlled trials, ORION-10 and ORION-11, published in the New England Journal of Medicine in 2020. ORION-10 enrolled 1,561 patients with atherosclerotic cardiovascular disease (ASCVD) who were already on maximally tolerated statin therapy. ORION-11 enrolled 1,617 patients with ASCVD or ASCVD risk equivalents. Both trials used the same dosing schedule: subcutaneous injections on day 1, at 3 months, and then every 6 months thereafter.

At 510 days, inclisiran 284 mg reduced LDL-C by 52.3% in ORION-10 and by 49.9% in ORION-11 compared with placebo (P<0.001 for both) [1]. The safety profile was comparable to placebo except for mild injection-site reactions in roughly 5% of participants.

Real-World Inclisiran Data

Real-world registries confirm the trial findings carry over to clinical practice. A 2023 analysis of the VICTORION-REAL program across European centers found that patients who received inclisiran in routine cardiology clinics achieved mean LDL-C reductions of approximately 48% at 6 months, consistent with the ORION program results. Adherence in that registry was notably high: 89% of patients received their 6-month injection on schedule, a figure that contrasts with adherence rates reported for daily oral lipid-lowering agents.

Mechanism Detail

Inclisiran is taken up by hepatocytes via the asialoglycoprotein receptor after subcutaneous injection. Once inside the cell, it loads into the RNA-induced silencing complex (RISC) and catalytically cleaves PCSK9 mRNA. Because a single inclisiran molecule can recycle and cleave multiple mRNA copies, the drug's effect persists for 6 months from a single dose. This mechanism explains why the twice-yearly schedule produces continuous LDL-C lowering rather than pulsatile suppression.

Losartan: Clinical Trial Evidence

The LIFE Trial

The Losartan Intervention For Endpoint reduction in hypertension (LIFE) trial, published in The Lancet in 2002, remains the foundational outcomes trial for losartan. It enrolled 9,193 patients aged 55 to 80 with essential hypertension and left ventricular hypertrophy (LVH) on ECG. Patients were randomized to losartan 50 to 100 mg once daily or atenolol 50 to 100 mg once daily, both with optional hydrochlorothiazide, for a mean follow-up of 4.8 years.

Losartan reduced the primary composite endpoint of cardiovascular death, stroke, and myocardial infarction by 13% compared with atenolol (relative risk 0.87, 95% CI 0.77 to 0.98, P<0.021), driven mainly by a 25% reduction in fatal and non-fatal stroke [2]. Systolic blood pressure fell by a mean of 30.2 mmHg in the losartan group from a baseline of approximately 174 mmHg.

Renal and Diabetic Nephropathy Indication

The RENAAL trial (N=1,513) demonstrated that losartan 50 to 100 mg daily reduced the composite of doubling of serum creatinine, end-stage renal disease, or death by 16% compared with placebo in patients with type 2 diabetes and nephropathy, independent of its blood pressure effect. This kidney-protective evidence led to a specific FDA labeling update and makes losartan irreplaceable for that patient population.

Real-World Losartan Adherence Data

Daily oral antihypertensives face a persistent adherence challenge. A 2020 analysis of pharmacy claims data from over 300,000 US hypertension patients found that medication possession ratios for ARBs, including losartan, averaged 68% at 12 months, meaning roughly one-third of patients had gaps in coverage. Losartan's generic availability since 2010 has made it one of the most affordable antihypertensives at under $10 per month at most US pharmacies, which partially offsets adherence barriers driven by cost.

Head-to-Head Comparison: Key Parameters

Because no randomized trial has directly compared inclisiran with losartan (they treat different conditions), the table below synthesizes the best available trial and registry data.

| Parameter | Inclisiran (Leqvio) | Losartan | |---|---|---| | Drug class | siRNA, PCSK9 inhibitor | ARB | | LDL-C reduction | ~50% vs. Placebo | Negligible (<5%) | | Systolic BP reduction | No significant effect | ~10-14 mmHg in LIFE | | Dosing | SC injection, twice yearly | Oral, once daily | | Renal protection | Not approved for this | Yes, diabetic nephropathy | | Stroke reduction | No dedicated CVOT yet | 25% vs. Atenolol in LIFE | | Cost (US, 2024) | ~$3,500/dose without coverage | ~$10/month generic | | Adherence (real-world) | ~89% on-schedule injection | ~68% medication possession ratio | | Common side effects | Injection-site reactions (5%) | Dizziness, hyperkalemia, dry cough rare (vs. ACEi) | | Pregnancy | Contraindicated | Contraindicated |

Who Should Receive Inclisiran vs Losartan (or Both)

Inclisiran Candidates

The FDA approval for inclisiran covers adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH), as an adjunct to diet and maximally tolerated statin therapy. The American College of Cardiology (ACC) 2022 Expert Consensus Decision Pathway for PCSK9 inhibitors notes that PCSK9-targeting agents are appropriate when LDL-C remains at 70 mg/dL or above in very high-risk ASCVD patients despite optimal statin plus ezetimibe therapy.

Patients who struggle with daily medication schedules are particularly suited for inclisiran's biannual regimen. The drug is typically administered in a clinical office setting, which also allows a care touchpoint every 6 months.

Losartan Candidates

Losartan is appropriate for adults with hypertension who need RAAS blockade, patients with diabetic nephropathy (type 2 diabetes, serum creatinine 1.3 to 3.0 mg/dL, proteinuria), and as an alternative to ACE inhibitors in patients who develop ACE-inhibitor-associated cough. The Eighth Joint National Committee (JNC 8) guidelines recommend ARBs as first-line antihypertensives in adults with diabetes or chronic kidney disease.

The Overlap: Patients Who Need Both

A 65-year-old with established ASCVD, LDL-C of 88 mg/dL on rosuvastatin 40 mg, blood pressure of 148/90 mmHg, and an eGFR of 55 mL/min/1.73 m² is a candidate for both drugs simultaneously. Inclisiran addresses residual LDL-C risk. Losartan manages blood pressure and may slow further GFR decline. The two drugs have no known pharmacokinetic interaction because inclisiran acts exclusively in hepatocytes and losartan is metabolized by CYP2C9 in the liver with a separate pharmacokinetic profile.

Safety Profiles Compared

Inclisiran Safety

Across ORION-10 and ORION-11, the most common adverse event attributable to inclisiran was injection-site reactions, occurring in 4.7% of treated patients vs. 0.5% with placebo. Rates of liver enzyme elevation, myalgia, and new-onset diabetes were similar between inclisiran and placebo groups, which distinguishes it favorably from high-intensity statins. No clinically meaningful drug-drug interactions have been identified, consistent with its RNA-based mechanism.

The FDA label carries no black-box warning. Inclisiran is contraindicated in pregnancy and lactation.

Losartan Safety

Losartan's principal safety concerns are hyperkalemia (particularly in patients with CKD or concurrent potassium-sparing diuretics), hypotension on first dose, and acute kidney injury in volume-depleted patients. Unlike ACE inhibitors, losartan does not inhibit bradykinin degradation, so the dry-cough rate is substantially lower (approximately 3% vs. 10 to 15% with ACE inhibitors). Angioedema remains possible but is rare compared with ACE inhibitors.

Losartan is pregnancy category D and absolutely contraindicated in the second and third trimesters due to fetal renal toxicity.

Real-World Evidence Summary: What Registries Add Beyond Trials

Randomized controlled trials optimize for internal validity. Real-world registries and claims databases answer a different question: what happens when less-selected patients receive these drugs in ordinary clinical settings?

Inclisiran in Practice

The ORION-REAL real-world program and the UK Biobank pharmacoepidemiology analyses both find that the magnitude of LDL-C lowering observed in ORION-10 and ORION-11 replicates in routine care. Patients with heterozygous FH, who are systematically underrepresented in general cardiovascular trials, achieve LDL-C reductions of 44 to 53% in registry data, consistent with the phase 3 figures.

One clinical gap in the real-world evidence base: cardiovascular outcome trial data for inclisiran are not yet published. The ORION-4 trial (approximately 15,000 patients) is ongoing, with primary completion expected in 2026. Until those results are available, inclisiran's MACE reduction is inferred from LDL-C surrogacy rather than direct endpoint measurement. Every 1 mmol/L reduction in LDL-C is associated with approximately a 22% reduction in major cardiovascular events based on Cholesterol Treatment Trialists' Collaboration meta-analyses (N>170,000 patient-years), which provides a reasonable bridge estimate.

Losartan in Practice

Large US claims analyses confirm that generic losartan's real-world effectiveness mirrors LIFE-trial results for blood pressure outcomes, though adherence gaps reduce the population-level benefit. A 2019 retrospective cohort study in JAMA Internal Medicine found that patients who filled ARB prescriptions consistently over 24 months had 17% fewer major cardiovascular events than those with adherence below 50%, independent of baseline blood pressure readings.

Formulary and Cost Considerations

Inclisiran's US list price is approximately $3,500 per injection (roughly $7,000 annually), though Novartis's outcomes-based contracting arrangements with several large payers link reimbursement to measured LDL-C response. Medicare Part B covers inclisiran as a physician-administered drug (not Part D), which changes the out-of-pocket calculus for patients 65 and older. Prior authorization requirements are common, typically requiring documentation of an LDL-C at or above 70 mg/dL on maximally tolerated statin plus ezetimibe.

Losartan is available as a generic at most US pharmacies for under $15 per 30-day supply without insurance. GoodRx-type discount programs bring the cost below $10 per month in many markets. No prior authorization is required in standard formularies.

Prescribing Considerations from the HealthRX Medical Team

The clinicians who review HealthRX content are asked this question most frequently in three scenarios: (1) a patient with high LDL-C and uncontrolled hypertension asking which drug to prioritize, (2) a patient confused by a formulary substitution notice, and (3) a patient who has been prescribed both drugs and wants to know if one can be dropped.

For scenario 1: prescribe both when both risk factors are present. LDL-C goal of <70 mg/dL in very high-risk patients and a systolic BP goal of <130 mmHg per ACC/AHA 2017 guidelines are separate targets requiring separate drug classes.

For scenario 2: payers cannot legally substitute inclisiran with losartan or vice versa because they have different active moieties and no shared indication. If a substitution notice arrives, it almost certainly reflects a clerical or coding error.

For scenario 3: neither drug should be discontinued without physician review. The two drugs address different risk factors and their combined use is appropriate in the right patient.